Tonix’s TONMYA Surges, Pipeline Expands | Business and Finance News

Tonix Pharmaceuticals is exploding on the scene with TONMYA, their groundbreaking fibromyalgia drug that’s tripled sales to $11 million in Q2 2026—driven by soaring prescriptions and patient refills. With a new sales force rolling out, they’re accelerating access for patients who’ve waited over 15 years for effective treatment. But this isn’t just about one hit: Tonix is also launching Phase Two trials for TNX-102 SL (depression) and TNX-4800 (Lyme disease prevention)—the latter revolutionary because it blocks infection inside the tick itself. Early Lyme results are promising, with manufacturing underway and enrollment set to begin in early 2027. Managed access agreements are already driving coverage growth, fueling confidence in sustained momentum. Tonix isn’t chasing hype—they’re building a pipeline of real solutions for unmet needs, one breakthrough at a time. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/27da5b110a87d5f6